Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 19/20 | 1.00 |
| ▸ | THRB | P10828 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.68 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23245074 | 0.94 | THRA (0.88) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL2927895 | 0.86 | THRA (1.00) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL13176156 | 0.85 | THRA (0.74) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL14627902 | 0.85 | THRB (0.74) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL24450095 | 0.83 | THRA (0.70) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL2920575 | 0.83 | THRB (0.70) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL2927758 | 0.82 | THRA (0.70) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL25874297 | 0.82 | THRB (0.69) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| SCHEMBL2927861 | 0.81 | THRA (0.68) | THRATHRBCYP2C9CYP2C8UGT1A1 | |
| Resmetirom SCHEMBL2927241 | 0.81 | THRA (1.00) | THRATHRBCYP2C9CYP2C8UGT1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919878-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. Hoffmann-Roche AG (CH) | 2008-05-14 | — | — | EP | claimed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | claimed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119431265-A | Compound as thyroid hormone receptor agonist | 南京瑞捷医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| CN-113474335-B | Compounds and their use as thyroid hormone receptor agonists | 南京瑞捷医药科技有限公司 | 2024-12-03 | — | — | CN | disclosed |
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | NANJING RUIJIE PHARMA CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-7452882-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452882-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452882-B2 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. (US) | 2008-11-18 | — | — | US | disclosed |
| EP-1919878-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. Hoffmann-Roche AG (CH) | 2008-05-14 | — | — | EP | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032494-A1 | Thyroid hormone analogs | HOFFMANN-LA ROCHE INC. | 2007-02-08 | — | — | US | disclosed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009913-A1 | PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162161-A1 | Novel compounds and their uses as thyroid hormone receptor agonists | THRA, THRB, TSHR | THRA 1/4885THRB 2/4885CYP2C9 1825/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | THRA 2/4885THRB 1/4885CYP2C9 3117/4885 |
| US-20070032494-A1 | Thyroid hormone analogs | THRA, THRB, TPO | THRA 1/4885THRB 2/4885CYP2C9 746/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | THRA 2/4885THRB 1/4885CYP2C9 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.